Vontobel Holding Ltd. Has $2.44 Million Position in BioNTech SE (NASDAQ:BNTX)

Vontobel Holding Ltd. lifted its position in shares of BioNTech SE (NASDAQ:BNTX) by 24.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,385 shares of the company’s stock after buying an additional 4,227 shares during the period. Vontobel Holding Ltd.’s holdings in BioNTech were worth $2,437,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the company. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new position in shares of BioNTech during the fourth quarter worth about $1,118,000. Van ECK Associates Corp boosted its position in shares of BioNTech by 25.1% during the fourth quarter. Van ECK Associates Corp now owns 118,418 shares of the company’s stock worth $13,493,000 after buying an additional 23,733 shares during the period. abrdn plc raised its holdings in BioNTech by 70.7% during the fourth quarter. abrdn plc now owns 385,668 shares of the company’s stock worth $43,947,000 after acquiring an additional 159,676 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in BioNTech by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 20,899 shares of the company’s stock worth $2,381,000 after acquiring an additional 1,960 shares in the last quarter. Finally, Sivik Global Healthcare LLC bought a new stake in BioNTech during the fourth quarter worth about $1,709,000. 15.52% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently issued reports on BNTX. Canaccord Genuity Group upped their target price on BioNTech from $171.00 to $171.44 and gave the stock a “buy” rating in a report on Wednesday, November 27th. The Goldman Sachs Group upgraded BioNTech from a “neutral” rating to a “buy” rating and upped their target price for the stock from $90.00 to $137.00 in a report on Friday, November 8th. Evercore ISI upgraded BioNTech from an “in-line” rating to an “outperform” rating and upped their target price for the stock from $110.00 to $125.00 in a report on Tuesday, November 19th. Truist Financial assumed coverage on BioNTech in a report on Friday, January 10th. They set a “buy” rating and a $172.00 target price on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $150.00 price objective on shares of BioNTech in a research note on Monday, November 18th. Three investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $142.72.

BioNTech Price Performance

Shares of NASDAQ BNTX opened at $119.83 on Monday. The firm has a market cap of $28.73 billion, a P/E ratio of -57.06 and a beta of 0.17. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. BioNTech SE has a 1-year low of $76.53 and a 1-year high of $131.49. The business’s 50 day moving average is $117.22 and its 200-day moving average is $109.62.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.